Mimosa 5 Adverse Reactions

Mosapride was well tolerated in clinical trials, with only minor adverse events such as diarrhoea/loose stools, dry mouth, malaise and headache being most commonly reported (<5% of patients).
According to physician-rated assessments in phase III trials, Mosapride was considered to be safe in 96.6% of patients with gastro-oesophageal reflux disease and 97.5% of patients with chronic gastritis.
Adverse events occurred in 2.71% (23 of 848) of patients with dyspepsia who had received Mosapride for more than 2 weeks, according to data from the post-marketing surveillance study. The most common adverse events were abdominal pain and loose stools (both 0.35%). No serious adverse events were reported.
Abnormal laboratory test values reported in clinical trials included eosinophilia (1.1%), elevated triglycerides (1.0%), and elevated AST, ALT and gamma glutamyl transpeptidase levels (all 0.4%).
There were no reports of QT interval prolongation associated with Mosapride treatment. However, there has been a single case report of Torsades de pointes ventricular tachycardia in a patient with hypokalemia who was receiving combination therapy with Mosapride and flecainide.